Residual Inflammatory Risk ASCVD CKD

CE / CME

Expert Insights on Targeting Residual Inflammatory Risk in ASCVD and CKD

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurses: 1.00 Nursing contact hour

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: July 22, 2024

Expiration: July 21, 2025

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC, discusses strategies for improving the care of patients with ASCVD and CKD, including how to target patients’ inflammatory risk using expert-informed guidelines.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary. To learn more about the targeting residual inflammatory risk in ASCVD and CKD, access other program activities here

Clinical Care Options plans to measure the educational impact of this activity. The question will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your response will be aggregated for analysis, and your specific response will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Rate your agreement with the following statement: I understand the rationale for ordering a high-sensitivity C-reactive protein (hsCRP) level to assess and mitigate residual risk of atherosclerotic cardiovascular disease (ASCVD) in patients with chronic kidney disease (CKD).

What is the pathologic role of the NLRP3 inflammasome complex in systemic inflammation in patients with CKD at risk for ASCVD? 

A 55-year-old man with stable ASCVD, type 2 diabetes (T2D), and CKD (eGFR 53 mL/min/1.73m2) is currently on maximized atorvastatin. His blood pressure and A1C are at goal, low-density lipoprotein cholesterol (LDL-C) is 57 mg/dL, and hsCRP is 3.5 mg/L. Which of the following have demonstrated the potential to reduce residual inflammatory risk in this patient?